DE202019101081U1 - lavender gum - Google Patents
lavender gum Download PDFInfo
- Publication number
- DE202019101081U1 DE202019101081U1 DE202019101081.9U DE202019101081U DE202019101081U1 DE 202019101081 U1 DE202019101081 U1 DE 202019101081U1 DE 202019101081 U DE202019101081 U DE 202019101081U DE 202019101081 U1 DE202019101081 U1 DE 202019101081U1
- Authority
- DE
- Germany
- Prior art keywords
- chewing gum
- gum
- lavender oil
- lavender
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000178870 Lavandula angustifolia Species 0.000 title 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 title 1
- 239000001102 lavandula vera Substances 0.000 title 1
- 235000018219 lavender Nutrition 0.000 title 1
- 229940112822 chewing gum Drugs 0.000 claims abstract description 18
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 18
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims abstract description 12
- 239000003921 oil Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000004392 Polyglycitol syrup Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 235000019451 polyglycitol syrup Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 235000016804 zinc Nutrition 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/10—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Confectionery (AREA)
Abstract
Kaugummi, umfassend eine Kaumasse zwischen 1 g und 5 g, in der ein Anteil zwischen 0,1% und 1% Öl aus Blüten von Lavanduala officinalis, Lavendelöl genannt, enthalten ist.Chewing gum comprising a gum between 1 g and 5 g containing between 0.1% and 1% oil of flowers of Lavanduala officinalis, called lavender oil.
Description
Die vorliegende Erfindung betrifft einen Kaugummi mit Lavendelöl.The present invention relates to a chewing gum with lavender oil.
Aus der
Aufgabe der Erfindung ist es, die Verwendung von Lavendelöl zu verbessern.The object of the invention is to improve the use of lavender oil.
Die Aufgabe wird durch die Merkmale der unabhängigen Ansprüche gelöst. Bevorzugte Weiterbildungen sind Gegenstand der abhängigen Ansprüche.The object is solved by the features of the independent claims. Preferred developments are the subject of the dependent claims.
Gemäß einem Aspekt der Erfindung umfasst ein Kaugummi eine Kaumasse zwischen 1 g und 5 g, in der ein Anteil zwischen 0,1% und 1% Öl aus Blüten von Lavanduala officinalis, Lavendelöl genannt, enthalten ist.According to one aspect of the invention, a chewing gum comprises a chewing gum between 1 g and 5 g, which contains a proportion of between 0.1% and 1% oil of flowers of Lavanduala officinalis, called lavender oil.
Dem angegebenen Kaugummi liegt die Erkenntnis zugrunde, dass eine orale Aufnahme von Lavendelöl zu Nebenwirkungen führen kann, die sich in vorübergehendem Aufstoßen, Übelkeit oder Verstopfung zeigen. Durch eine Senkung der oralen Aufnahme von Lavendelöl lässt sich das Risiko der Nebenwirkungen senken. Hier greift der Vorschlag an, das Lavendelöl nicht in Form einer herkömmlichen Tablette, Kapsel oder dergleichen sondern über mit einem Kaugummi zu verabreichen. Die Mundschleimhäute nehmen das Lavendelöl deutlich besser und effektiver auf, so dass eine stimmungsaufhellende Wirkung bereits mit weniger als einem Zehntel der Dosis erreicht werden kann, als im Stand der Technik.The stated chewing gum is based on the finding that oral ingestion of lavender oil can lead to side effects, which are manifested in temporary regurgitation, nausea or constipation. Lowering the oral intake of lavender oil can reduce the risk of side effects. Here is the suggestion to administer the lavender oil not in the form of a conventional tablet, capsule or the like but with a chewing gum. The oral mucous membranes absorb the lavender oil much better and more effectively, so that a mood-enhancing effect can be achieved with less than one tenth of the dose than in the prior art.
In einer bevorzugten Weiterbildung des angegebenen Kaugummis beträgt der Anteil an Lavendelöl zwischen 0,2% und 0,4%.In a preferred embodiment of the specified chewing gum, the proportion of lavender oil is between 0.2% and 0.4%.
In einer anderen Weiterbildung des angegebenen Kaugummis umfasst die Kaumasse wenigstens einen der folgenden Zuckeralkohole: Sorbit, Mannit, Isomalt, Maltit, Lactit, Xylit, Erythrit, Polyglycitolsirup.In another development of the specified chewing gum, the chewing mass comprises at least one of the following sugar alcohols: sorbitol, mannitol, isomalt, maltitol, lactitol, xylitol, erythritol, polyglycitol syrup.
In einer noch anderen Weiterbildung umfasst der angegebene Kaugummi einen Säureregulator, der besonders bevorzugt Zitronensäure sein kann.In yet another embodiment, the specified chewing gum comprises an acidity regulator, which may more preferably be citric acid.
In einer weiteren Weiterbildung umfasst der angegebene Kaugummi einen Zusatzgehalt eines oder mehrerer Zusatzstoffe, die aus Nicotinsäure, Pantothensäure, Colecalciferol, Biotin und Zink ausgewählt sind. Dabei kann der Zusatzgehalt zwischen 0,1% und 1%, vorzugsweise zwischen 0,15% und 0,35% betragen.In a further development, the stated chewing gum comprises an additional content of one or more additives selected from nicotinic acid, pantothenic acid, colecalciferol, biotin and zinc. The additional content may be between 0.1% and 1%, preferably between 0.15% and 0.35%.
ZITATE ENTHALTEN IN DER BESCHREIBUNG QUOTES INCLUDE IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.
Zitierte PatentliteraturCited patent literature
- EP 1796702 B1 [0002]EP 1796702 B1 [0002]
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE202019101081.9U DE202019101081U1 (en) | 2019-02-25 | 2019-02-25 | lavender gum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE202019101081.9U DE202019101081U1 (en) | 2019-02-25 | 2019-02-25 | lavender gum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE202019101081U1 true DE202019101081U1 (en) | 2019-04-29 |
Family
ID=66548549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE202019101081.9U Expired - Lifetime DE202019101081U1 (en) | 2019-02-25 | 2019-02-25 | lavender gum |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE202019101081U1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020117395A1 (en) | 2020-07-01 | 2022-01-05 | Happygum G.m.b.H | Composition used as a mood-regulating stimulant |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1796702A1 (en) | 2004-10-06 | 2007-06-20 | Dr. Willmar Schwabe GmbH & Co. KG | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress |
-
2019
- 2019-02-25 DE DE202019101081.9U patent/DE202019101081U1/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1796702A1 (en) | 2004-10-06 | 2007-06-20 | Dr. Willmar Schwabe GmbH & Co. KG | Use of lavender oil for the prophylaxis and treatment of neuro asthenia, somatization disorders and other diseases associated with stress |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020117395A1 (en) | 2020-07-01 | 2022-01-05 | Happygum G.m.b.H | Composition used as a mood-regulating stimulant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4007705C1 (en) | ||
| EP2613793A1 (en) | Nasal spray | |
| DE202019101081U1 (en) | lavender gum | |
| DE69921662T2 (en) | USE OF GINGKO BILOBA EXTRACTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF AMYOTROPH LATERAL SCLEROSIS | |
| DE19758564A1 (en) | Formulation of a combination of morphine and an alpha¶2¶ adrenergic agonist and their use | |
| WO2001005378A1 (en) | Ambroxol-containing lozenge | |
| EP1286657B1 (en) | Nasal ointment based on white petroleum jelly | |
| WO2006111258A1 (en) | Anti-irritating cough mixture containing extracts from island moss and mallow | |
| DE202014100305U1 (en) | Transparent gel | |
| DE2922670C2 (en) | Chewable dosage form | |
| DE19733094A1 (en) | Formulation based on ascorbic acid with improved color stability | |
| WO2015177147A1 (en) | Cough medicine containing ambroxol hydrochloride | |
| DE102005053317B4 (en) | Use of a composition with a mixture of vegetable extracts of fennel, thyme and eucalyptus | |
| EP1775303A1 (en) | Topiramate and pharmaceutical compositions thereof | |
| DE102020117395A1 (en) | Composition used as a mood-regulating stimulant | |
| Brumlik | Pädagogik als kritische Kulturwissenschaft | |
| DE202022106123U1 (en) | A novel polytherapeutic formulation with anti-asthmatic potential | |
| DE102005056054B3 (en) | A pharmaceutical composition for the treatment and / or prevention of at least one respiratory disease | |
| DE202015000039U1 (en) | Non-alcoholic Swedish bitter | |
| Heil | Athanasius und Basilius | |
| AT17388U1 (en) | Composition containing several plant extracts | |
| DE202021106655U1 (en) | Herbal mouthwash composition for cleaning the mouth and curing/treating periodontal disease | |
| AT17333U1 (en) | Composition containing several plant extracts | |
| Oexmann | Tierschutzrelevante Strafbarkeit des Pferdesportlers. | |
| DE2038827C3 (en) | Oral and dental care products for the prevention and improvement of gingivitis and for treating periodontal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification | ||
| R163 | Identified publications notified | ||
| R156 | Lapse of ip right after 3 years |